Cargando…

Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients

BACKGROUND: Epstein–Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) which is prevalent in South China, and its association with systemic lupus erythematosus (SLE) or other autoimmune diseases has not been studied in the mainland of China. The EBV serological tests have been perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jingtao, Yan, Wenjuan, Xu, Shaoxia, Wang, Qiaofeng, Zhang, Weihong, Liu, Wenjing, Ni, Anping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832223/
https://www.ncbi.nlm.nih.gov/pubmed/29494658
http://dx.doi.org/10.1371/journal.pone.0193171
_version_ 1783303289856589824
author Cui, Jingtao
Yan, Wenjuan
Xu, Shaoxia
Wang, Qiaofeng
Zhang, Weihong
Liu, Wenjing
Ni, Anping
author_facet Cui, Jingtao
Yan, Wenjuan
Xu, Shaoxia
Wang, Qiaofeng
Zhang, Weihong
Liu, Wenjing
Ni, Anping
author_sort Cui, Jingtao
collection PubMed
description BACKGROUND: Epstein–Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) which is prevalent in South China, and its association with systemic lupus erythematosus (SLE) or other autoimmune diseases has not been studied in the mainland of China. The EBV serological tests have been performed on patients with various diseases or manifestations for years at our institution and their values need to be evaluated. METHODS: For routine medical purposes, anti-EB viral capsid antigen (VCA) IgG, IgA and IgM antibodies, anti-EBV diffuse early antigen (EA-D) IgA antibodies, and anti-EBV nuclear antigen-1(EBNA-1) IgG antibodies were tested with commercial enzyme-linked immunosorbent assay (ELISA) in patients visiting Peking Union Medical College Hospital between 2013 and 2017. The test results were analyzed in this retrospective study. RESULTS: There were a total of 11122 serum samples available to be tested in the study. As indicators of past EBV infection, the prevalence of VCA-IgG/EBNA1-IgG were 66.6%/58.5%, 84.3%/78.8%, 92.9%/87.0% and 98.5%/95.4% in patients aged under 5 years, 6–10 years, 11–20 years and 21–30 years old, respectively, and these values maintained at this highest rate as age increased further. The prevalence of VCA-IgM, as a parameter of acute EBV infection, was 14.6%, 10.2%, 10.4%, 6.3% and 3.1% in patients aged under 5 years, 6–10 years,11–20 years, 21–30 years, 31–40 years old, respectively, and decreased to 2%~3% in older patients. Patients with elevated serum liver enzymes were more likely to have a higher prevalence of EA/D IgA antibody (P < 0.01) and young patients (≤30 years) with lymphadenopathy were more likely to have higher prevalence of VCA-IgM antibody (P < 0.01). The prevalence of VCA-IgA and EAD-IgA were 87.0% and 59.2% in NPC patients, respectively, and both were significantly higher (P < 0.001) than that in non-NPC patients. The prevalence of VCA-IgA was 45.4% and 25.6% in SLE patients and patients with other autoimmune diseases, respectively, which were significantly (P < 0.001) and mildly (P = 0.039) higher than their controls. In pediatric SLE patients between 6 and10 years old, the prevalence of VCA-IgG, VCA-IgA and EBNA1-IgG was 100%, 59.5% and 100%, respectively, all being significantly higher than the age (6-10y) related controls (P< 0.01). In the 705 cerebral spinal fluid (CSF) specimens, VCA-IgG, VCA-IgM, VCA-IgA and EAD-IgA were found to be positive in 12.1%, 0.15%, 0.25% and 0.25%, respectively. There were 157 paired specimens (CSF and serum were collected simultaneously) and VCA-IgG was identified as positive in 12.7% of the CSF and 100% of the serum specimens. CONCLUSIONS: Around 98% of Chinese patients were infected with EBV before 30 years of age and the highest rate of acute EBV infection were observed in patients under 5 years old. EBV infection was found to be associated with elevated serum liver enzymes, NPC and SLE. Acute anti-EBV antibody was valued for young patients with lymphadenopathy but limited value for CNS neuropathy.
format Online
Article
Text
id pubmed-5832223
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58322232018-03-23 Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients Cui, Jingtao Yan, Wenjuan Xu, Shaoxia Wang, Qiaofeng Zhang, Weihong Liu, Wenjing Ni, Anping PLoS One Research Article BACKGROUND: Epstein–Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) which is prevalent in South China, and its association with systemic lupus erythematosus (SLE) or other autoimmune diseases has not been studied in the mainland of China. The EBV serological tests have been performed on patients with various diseases or manifestations for years at our institution and their values need to be evaluated. METHODS: For routine medical purposes, anti-EB viral capsid antigen (VCA) IgG, IgA and IgM antibodies, anti-EBV diffuse early antigen (EA-D) IgA antibodies, and anti-EBV nuclear antigen-1(EBNA-1) IgG antibodies were tested with commercial enzyme-linked immunosorbent assay (ELISA) in patients visiting Peking Union Medical College Hospital between 2013 and 2017. The test results were analyzed in this retrospective study. RESULTS: There were a total of 11122 serum samples available to be tested in the study. As indicators of past EBV infection, the prevalence of VCA-IgG/EBNA1-IgG were 66.6%/58.5%, 84.3%/78.8%, 92.9%/87.0% and 98.5%/95.4% in patients aged under 5 years, 6–10 years, 11–20 years and 21–30 years old, respectively, and these values maintained at this highest rate as age increased further. The prevalence of VCA-IgM, as a parameter of acute EBV infection, was 14.6%, 10.2%, 10.4%, 6.3% and 3.1% in patients aged under 5 years, 6–10 years,11–20 years, 21–30 years, 31–40 years old, respectively, and decreased to 2%~3% in older patients. Patients with elevated serum liver enzymes were more likely to have a higher prevalence of EA/D IgA antibody (P < 0.01) and young patients (≤30 years) with lymphadenopathy were more likely to have higher prevalence of VCA-IgM antibody (P < 0.01). The prevalence of VCA-IgA and EAD-IgA were 87.0% and 59.2% in NPC patients, respectively, and both were significantly higher (P < 0.001) than that in non-NPC patients. The prevalence of VCA-IgA was 45.4% and 25.6% in SLE patients and patients with other autoimmune diseases, respectively, which were significantly (P < 0.001) and mildly (P = 0.039) higher than their controls. In pediatric SLE patients between 6 and10 years old, the prevalence of VCA-IgG, VCA-IgA and EBNA1-IgG was 100%, 59.5% and 100%, respectively, all being significantly higher than the age (6-10y) related controls (P< 0.01). In the 705 cerebral spinal fluid (CSF) specimens, VCA-IgG, VCA-IgM, VCA-IgA and EAD-IgA were found to be positive in 12.1%, 0.15%, 0.25% and 0.25%, respectively. There were 157 paired specimens (CSF and serum were collected simultaneously) and VCA-IgG was identified as positive in 12.7% of the CSF and 100% of the serum specimens. CONCLUSIONS: Around 98% of Chinese patients were infected with EBV before 30 years of age and the highest rate of acute EBV infection were observed in patients under 5 years old. EBV infection was found to be associated with elevated serum liver enzymes, NPC and SLE. Acute anti-EBV antibody was valued for young patients with lymphadenopathy but limited value for CNS neuropathy. Public Library of Science 2018-03-01 /pmc/articles/PMC5832223/ /pubmed/29494658 http://dx.doi.org/10.1371/journal.pone.0193171 Text en © 2018 Cui et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cui, Jingtao
Yan, Wenjuan
Xu, Shaoxia
Wang, Qiaofeng
Zhang, Weihong
Liu, Wenjing
Ni, Anping
Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title_full Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title_fullStr Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title_full_unstemmed Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title_short Anti-Epstein–Barr virus antibodies in Beijing during 2013–2017: What we have found in the different patients
title_sort anti-epstein–barr virus antibodies in beijing during 2013–2017: what we have found in the different patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832223/
https://www.ncbi.nlm.nih.gov/pubmed/29494658
http://dx.doi.org/10.1371/journal.pone.0193171
work_keys_str_mv AT cuijingtao antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT yanwenjuan antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT xushaoxia antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT wangqiaofeng antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT zhangweihong antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT liuwenjing antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients
AT nianping antiepsteinbarrvirusantibodiesinbeijingduring20132017whatwehavefoundinthedifferentpatients